Josef Ozer, Ph.D. - Publications

Affiliations: 
Pharmacology Boston University School of Medicine, Boston, MA 
Area:
Pharmacology

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Ratner MH, Farb DH, Ozer J, Feldman RG, Durso R. Younger age at onset of sporadic Parkinson's disease among subjects occupationally exposed to metals and pesticides. Interdisciplinary Toxicology. 7: 123-33. PMID 26109889 DOI: 10.2478/intox-2014-0017  1
2014 Brodfuehrer J, Rankin A, Edmonds J, Keegan S, Andreyeva T, Lawrence-Henderson R, Ozer J, Gao H, Bloom L, Boisvert A, Lam K, Lee J, LaBranche T, Syed J, Miao W, et al. Quantitative analysis of target coverage and germinal center response by a CXCL13 neutralizing antibody in a T-dependent mouse immunization model. Pharmaceutical Research. 31: 635-48. PMID 24190631 DOI: 10.1007/s11095-013-1185-2  1
2012 Wang M, Defranco D, Wright K, Quazi S, Chen J, Spencer-Pierce J, Zaghloul I, Pak R, Darvair R, Krishnan A, Perreault M, Sun L, Ozer J, Xin X. Decreased subcutaneous bioavailability of an Oxyntomodulin analog in a controlled release formulation could be caused by skin metabolism in rats Journal of Bioequivalence and Bioavailability. 4: 69-77. DOI: 10.4172/jbb.1000115  1
2012 Wang M, Defranco D, Wright K, Quazi S, Chen J, Spencer-Pierce J, Zaghloul I, Pak R, Darvair R, Krishnan A, Perreault M, Sun L, Ozer J, Xin X. Decreased subcutaneous bioavailability of an Oxyntomodulin analog in a controlled release formulation could be caused by skin metabolism in rats Journal of Bioequivalence and Bioavailability. 4: 69-77.  1
2011 Zhang Y, Li N, Brown PW, Ozer JS, Lai Y. Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples. Rapid Communications in Mass Spectrometry : Rcm. 25: 1715-24. PMID 21598331 DOI: 10.1002/rcm.5026  1
2010 Chetty RK, Ozer JS, Lanevschi A, Schuppe-Koistinen I, McHale D, Pears JS, Vonderscher J, Sistare FD, Dieterle F. A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association. Clinical Pharmacology and Therapeutics. 88: 260-2. PMID 20592723 DOI: 10.1038/clpt.2010.77  1
2010 Ozer JS, Chetty R, Kenna G, Koppiker N, Karamjeet P, Li D, Palandra J, Lanevschi A, Souberbielle BE, Ramaiah S. Recommendations to qualify biomarker candidates of drug-induced liver injury. Biomarkers in Medicine. 4: 475-83. PMID 20550481 DOI: 10.2217/bmm.10.9  1
2010 Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, Wahl D, Legay F, Holder D, Erdos Z, Vlasakova K, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnology. 28: 486-94. PMID 20458319 DOI: 10.1038/nbt.1627  1
2010 Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotechnology. 28: 478-85. PMID 20458318 DOI: 10.1038/nbt.1623  1
2010 Yu Y, Jin H, Holder D, Ozer JS, Villarreal S, Shughrue P, Shi S, Figueroa DJ, Clouse H, Su M, Muniappa N, Troth SP, Bailey W, Seng J, Aslamkhan AG, et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotechnology. 28: 470-7. PMID 20458317 DOI: 10.1038/nbt.1624  1
2010 Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature Biotechnology. 28: 455-62. PMID 20458315 DOI: 10.1038/nbt.1625  1
2010 Sistare FD, Dieterle F, Troth S, Holder DJ, Gerhold D, Andrews-Cleavenger D, Baer W, Betton G, Bounous D, Carl K, Collins N, Goering P, Goodsaid F, Gu YZ, Guilpin V, ... ... Ozer J, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nature Biotechnology. 28: 446-54. PMID 20458314 DOI: 10.1038/nbt.1634  1
2010 Ozer JS. A guidance for renal biomarker lead optimization and use in translational pharmacodynamics. Drug Discovery Today. 15: 142-7. PMID 20026239 DOI: 10.1016/j.drudis.2009.12.001  1
2010 Ozer JS, Chetty R, Kenna G, Palandra J, Zhang Y, Lanevschi A, Koppiker N, Souberbielle BE, Ramaiah SK. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regulatory Toxicology and Pharmacology : Rtp. 56: 237-46. PMID 19903504 DOI: 10.1016/j.yrtph.2009.11.001  1
2010 Ozer JS, Reagan WJ, Schomaker S, Palandra J, Baratta M, Ramaiah S. Translational Biomarkers of Acute Drug-Induced Liver Injury: The Current State, Gaps, and Future Opportunities Biomarkers: in Medicine, Drug Discovery, and Environmental Health. 203-236. DOI: 10.1002/9780470918562.ch9  1
2009 Ozer JS, Teitelbaum A. Novel prodromal biomarkers that are symptomatic of injury require histopathologic or clinical chemistry anchors to characterize activity. Journal of Pharmacological and Toxicological Methods. 60: 321-2. PMID 19632346 DOI: 10.1016/j.vascn.2009.07.005  1
2009 Palandra J, Prusakiewicz J, Ozer JS, Zhang Y, Heath TG. Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 2052-60. PMID 19535304 DOI: 10.1016/j.jchromb.2009.05.043  1
2008 Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 245: 194-205. PMID 18291570 DOI: 10.1016/j.tox.2007.11.021  1
2006 Howe ML, Mehmud ZF, Saha S, Buratovich M, Stutius EA, Schmidt HD, Lenon AL, Reddicks C, Ivanov GS, Przyborski SA, Ozer JS. Transcription Factor IIA tau is associated with undifferentiated cells and its gene expression is repressed in primary neurons at the chromatin level in vivo. Stem Cells and Development. 15: 175-90. PMID 16646664 DOI: 10.1089/scd.2006.15.175  1
2003 Ivanov GS, Kater JM, Jha SH, Stutius EA, Sabharwal R, Tricarico MD, Ginsburg GS, Ozer JS. Sp and GATA factors are critical for Apolipoprotein AI downstream enhancer activity in human HepG2 cells. Gene. 323: 31-42. PMID 14659877 DOI: 10.1016/j.gene.2003.08.014  1
2000 Ozer J, Moore PA, Lieberman PM. A testis-specific transcription factor IIA (TFIIAtau) stimulates TATA-binding protein-DNA binding and transcription activation. The Journal of Biological Chemistry. 275: 122-8. PMID 10617594 DOI: 10.1074/jbc.275.1.122  1
1999 Moore PA, Ozer J, Salunek M, Jan G, Zerby D, Campbell S, Lieberman PM. A human TATA binding protein-related protein with altered DNA binding specificity inhibits transcription from multiple promoters and activators. Molecular and Cellular Biology. 19: 7610-20. PMID 10523649  1
1998 Ozer J, Mitsouras K, Zerby D, Carey M, Lieberman PM. Transcription factor IIA derepresses TATA-binding protein (TBP)-associated factor inhibition of TBP-DNA binding. The Journal of Biological Chemistry. 273: 14293-300. PMID 9603936 DOI: 10.1074/jbc.273.23.14293  1
1998 Ozer J, Lezina LE, Ewing J, Audi S, Lieberman PM. Association of transcription factor IIA with TATA binding protein is required for transcriptional activation of a subset of promoters and cell cycle progression in Saccharomyces cerevisiae. Molecular and Cellular Biology. 18: 2559-70. PMID 9566876 DOI: 10.1128/MCB.18.5.2559  1
1997 Kim AL, Maher M, Hayman JB, Ozer J, Zerby D, Yates JL, Lieberman PM. An imperfect correlation between DNA replication activity of Epstein-Barr virus nuclear antigen 1 (EBNA1) and binding to the nuclear import receptor, Rch1/importin alpha. Virology. 239: 340-51. PMID 9434725 DOI: 10.1006/viro.1997.8874  1
1997 Lieberman PM, Ozer J, Gürsel DB. Requirement for transcription factor IIA (TFIIA)-TFIID recruitment by an activator depends on promoter structure and template competition. Molecular and Cellular Biology. 17: 6624-32. PMID 9343426  1
1996 Ozer J, Bolden AH, Lieberman PM. Transcription factor IIA mutations show activator-specific defects and reveal a IIA function distinct from stimulation of TBP-DNA binding. The Journal of Biological Chemistry. 271: 11182-90. PMID 8626665 DOI: 10.1074/jbc.271.19.11182  1
1995 Ginsburg GS, Ozer J, Karathanasis SK. Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4. The Journal of Clinical Investigation. 96: 528-38. PMID 7615825 DOI: 10.1172/JCI118065  1
1994 Ozer J, Moore PA, Bolden AH, Lee A, Rosen CA, Lieberman PM. Molecular cloning of the small (gamma) subunit of human TFIIA reveals functions critical for activated transcription. Genes & Development. 8: 2324-35. PMID 7958899  1
1994 Briggs RC, Briggs JA, Ozer J, Sealy L, Dworkin LL, Kingsmore SF, Seldin MF, Kaur GP, Athwal RS, Dessypris EN. The human myeloid cell nuclear differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q that are expressed specifically in hematopoietic cells. Blood. 83: 2153-62. PMID 7512843  1
1993 Ozer J, Chalkley R, Sealy L. Isolation of the CCAAT transcription factor subunit EFIA cDNA and a potentially functional EFIA processed pseudogene from Bos taurus: insights into the evolution of the EFIA/dbpB/YB-1 gene family. Gene. 124: 223-30. PMID 8444345 DOI: 10.1016/0378-1119(93)90397-L  1
1993 Ozer J, Chalkley R, Sealy L. Characterization of rat pseudogenes for enhancer factor I subunit A: ripping provides clues to the evolution of the EFIA/dbpB/YB-1 multigene family. Gene. 133: 187-95. PMID 8224907 DOI: 10.1016/0378-1119(93)90637-I  1
1990 Ozer J, Faber M, Chalkley R, Sealy L. Isolation and characterization of a cDNA clone for the CCAAT transcription factor EFIA reveals a novel structural motif. The Journal of Biological Chemistry. 265: 22143-52. PMID 1967130  1
Show low-probability matches.